Inventiva company profile
Company profile
Inventiva has 87 employees and is headquartered in Daix, France.
Patients with metabolic dysfunction-associated steatohepatitis, known as MASH, and with mucopolysaccharidoses are among the groups this company develops treatments for, in France and in other countries. Its activity centres on orally administered small molecules aimed at MASH and other diseases, and its research pipeline is at clinical and pre-clinical stages. Lanifibranor, a peroxisome proliferator-activated receptor agonist, is in the NATiV3 Phase 3 trial in adult patients with MASH. Odiparcil targets mucopolysaccharidoses, and a pre-clinical TGF-β program addresses idiopathic pulmonary fibrosis.
In the fiscal year ended 31 December 2025, revenue was 6.8 million euros, down 52.0% from the previous year, while the net loss reached 354.1 million euros. The accounts cover the twelve months to that date. The company employed 87 people and is headquartered in Daix, France; it was incorporated in 2011.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Headquarters
- 50 rue de Dijon, 21121, Daix
- Employees
- 87
- Chief executive
- Andrew Obenshain
- Founded
- 2011
- Fiscal year
- January - December
- Listing
- IVA · Euronext Paris
- Currency
- EUR
- ISIN
- FR0013233012
- Website
- inventivapharma.com
Inventiva and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| InventivaIVA | France | $890.8M | 87 | -5,980.9% | — |
| Pharming GroupPHARM | Netherlands | $841.25M | 407 | 12.8% | 36.1 |
| PhilogenPHIL | Italy | $905.96M | 230 | 79.1% | 3.67 |
| Basilea PharmaceuticaBSLN | Switzerland | $1.07B | 200 | 24.2% | 18.1 |
| GubraGUBRA | Denmark | $730.02M | 330 | -73.1% | — |
| Pharma MarPHM | Spain | $1.1B | 505 | 21.3% | 14.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
